Research programme: cancer therapeutics - Novonco

Drug Profile

Research programme: cancer therapeutics - Novonco

Alternative Names: Epigenetics modulators - Novonco Therapeutics; Kinase inhibitors - Novonco Therapeutics

Latest Information Update: 22 Aug 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novonco Therapeutics
  • Class Small molecules
  • Mechanism of Action Gene expression modulators; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acute myeloid leukaemia; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 19 Aug 2014 Early research in Acute myeloid leukaemia in USA (unspecified route)
  • 19 Aug 2014 Early research in Ovarian cancer in USA (unspecified route)
  • 19 Aug 2014 Early research in Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top